[China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2017 3Q17 Added 19,712 New Subscribers 3Q17 Revenue Up 18.6% YOY to RMB200.9 Million ($28.9 Million) 3Q17 Operating Income Reached RMB101.7 Million ($14.6 Million) Conference Call to be Held ]
[THE9 LIMITED Jun Zhu Chairman and Chief Executive Officer The9 Limited Announces Receipt of Nasdaq Notice of Deficiency The Companys management is looking into various options available to regain compliance and maintain its continued listing on The NASDAQ Global Market, and is also considering othe]
[China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2017 3Q17 Added 19,712 New Subscribers 3Q17 Revenue Up 18.6% YOY to RMB200.9 Million ($28.9 Million) 3Q17 Operating Income Reached RMB101.7 Million ($14.6 Million) Conference Call to be Held ]
[THE9 LIMITED Jun Zhu Chairman and Chief Executive Officer The9 Limited Announces Receipt of Nasdaq Notice of Deficiency The Companys management is looking into various options available to regain compliance and maintain its continued listing on The NASDAQ Global Market, and is also considering othe]
[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 21, 2017 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Provinc]
